Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Akebia Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was €289.9 Mil. Akebia Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was €313.6 Mil.
Therefore, Akebia Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.92.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Akebia Therapeutics Liabilities-to-Assets Related Terms
Akebia Therapeutics Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AX9 vs ORGO, EBS, TKNO: Liabilities-to-Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Liabilities-to-Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Akebia Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (FRA:AX9) has a Liabilities-to-Assets of 0.92 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Liabilities-to-Assets too high?
Akebia Therapeutics' current Liabilities-to-Assets is 0.92. Overall, Akebia Therapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Liabilities-to-Assets compare to ORGO and EBS?
Akebia Therapeutics' Liabilities-to-Assets of 0.92 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Drug Manufacturers company?
A good Liabilities-to-Assets depends on the Drug Manufacturers industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Liabilities-to-Assets is 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (FRA:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.05, compared to a current price of €1.15 — trading 9.2% above its estimated fair value. The current Liabilities-to-Assets is 0.92. Akebia Therapeutics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Akebia Therapeutics (FRA:AX9), the current Liabilities-to-Assets is 0.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued.
The current stock price of €1.15 is trading 9.2% above its estimated GF Value™ of €1.05.
GuruFocus considers Akebia Therapeutics to be Fairly Valued.
Key valuation signals for FRA:AX9:
Liabilities-to-Assets: 0.92
GF Value™: €1.05 vs. price of €1.15 (9.2% above fair value)
No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
54GF Score
Get the complete analysis for FRA:AX9
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AX9 has been successfully added to your 
